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Evidence for treating malaria with artemisinin-based 
combination therapy in the first trimester of pregnancy
Treatment of malaria during pregnancy requires 
balancing the need for radical cure while avoiding 
teratogenic exposure. In The Lancet Infectious Diseases, 
Makoto Saito and colleagues report the results of 
a systematic review and meta-analysis that used 
individual patient data on antimalarial efficacy and 
tolerability in pregnancy.1 This impressive undertaking 
comprises nearly all published evidence and clearly 
highlights the superiority of artemisinin-based combi-
nation therapy (ACT) over quinine monotherapy, 
building on previous studies that focused on ACT safety 
in the second and third trimesters.2
Quinine has been the only treatment for malaria in 
much of the world over the past four centuries, with 
the first reported use for a microscopically confirmed 
diagnosis of malaria during pregnancy in 1908.3 WHO 
recommends quinine for the treatment of malaria in the 
first trimester, ideally in combination with clindamycin. 
First-trimester use of ACTs is only advised when quinine 
is not available.4 However, because clindamycin is 
rarely available at the point of care in malaria-endemic 
countries, the vast majority of pregnant women 
diagnosed with first-trimester malaria are given quinine 
monotherapy, or an ACT if pregnancy is not recognised.5,6
Saito and colleagues found that quinine plus 
clindamycin had a similar PCR-corrected efficacy 
on day 28 compared to artemether-lumefantrine 
(AL; 99·9% vs 96·9%, respectively; adjusted hazard 
ratio 0·48 [95% CI 0·04–5·24]), whereas quinine 
monotherapy had an efficacy of only 87·7% (6·11, 
2·57–14·57) compared to AL. The substantially lower 
efficacy of quinine monotherapy versus AL is further 
evidence to support the change to WHO’s treatment 
guidelines recommended by the Malaria Policy Action 
Committee in 2016.7
Although only 33 of 4968 total episodes in the meta-
analysis were in their first trimester, there is no evidence 
to suggest that the relative efficacy of antimalarials in 
the first trimester would differ from treatment later in 
pregnancy. Moreover, the higher efficacy of artemisinin 
over quinine is more apparent in severe disease for 
which parenteral artemisinin is already the preferred 
option.4
It is difficult to draw conclusions regarding safety 
given the very small number of first-trimester preg-
nancies in this study. However, the safety of ACT in 
pregnancy is supported by data for 30 618 pregnancies 
(947 exposed to quinine and 717 exposed to ACTs 
in the first trimester) that showed that the risk of 
miscarriage and stillbirth are similar between ACTs and 
quinine. Compared with quinine, the risk of ACTs on 
miscarriage were 0·73 (95% CI 0·44–1·21) and the risk 
of ACT on stillbirth were 0·29 (0·08–1·02).8 Neither 
ACTs nor quinine were associated with an increased risk 
of stillbirth compared with no antimalarial treatment 
in the first trimester. Quinine administered in the 
first trimester was associated with increased risk of 
miscarriage compared with no antimalarial treatment, 
although ACTs were not. The risks of congenital 
malformations from quinine and ACTs were similar. 
These numbers are only sufficient to exclude a greater 
than approximately two-fold increase in the risk of 
miscarriage and stillbirth, underscoring the need for 
more data.8 However, it has taken two decades to 
collect the evidence to date, and it is unlikely that more 
data will be available soon. There is also the issue of 
poor tolerability associated with quinine, whereby a 
very high proportion of patients reported symptoms 
of cinchonism, including tinnitus, by day 7 of therapy.9 
These adverse effects might be so bothersome that 
therapy is discontinued prematurely, further reducing 
its efficacy. Effective treatment clearly reduces the risk 
of stillbirth caused by malaria infection.10 Therefore, 
even if it was ensured that all first-trimester women 
with parasitaemia receive quinine plus clindamycin for 
7 days, these patients might not be optimally served.
Today, there are insufficient safety data for the use 
of ACTs in first trimester to argue for their use in first 
trimester for scenarios in which malaria testing is not 
done before dosing (eg, mass drug administration) 
or for scenarios in which the drug is provided 
prophylactically (eg, intermittent preventive treatment 
in pregnancy). However, considering the evidence base 
of efficacy, adherence, and tolerability, the risk-benefit 
analysis for treatment favours the use of ACTs for 
confirmed malaria in the first trimester of pregnancy.7
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